[Current status of cytostatic therapy].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000477:Alkylating Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008938:Mitosis / Q000187:drug effects; D009362:Neoplasm Metastasis; D013942:Thymine Nucleotides / Q000096:biosynthesis
D000305:Adrenal Cortex Hormones; D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D013942:Thymine Nucleotides; D003561:Cytarabine; D015122:Mercaptopurine; D005472:Fluorouracil; D008727:Methotrexate
Derzeitiger Stand der zytostatischen Therapie